Guideline for Migraine Prophylaxis in Adults(257 KB)
Date added: 12th May 2026
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| Atogepant (Aquipta®) (UPDATED) | Green | Prophylaxis of migraine |
For preventing migraine in adults who have at least 4 migraine days per month and only if at least 3 preventive medicines have failed. See NICE TA973 for full details. To be prescribed in line with the LLR Migraine pathway |
| BETULA VERRUCOSA ALLERGEN EXTRACT (Itulazax®) | Orange | Moderate to severe allergic rhinitis/conjunctivitis caused by Birch pollen | |
| Cytisine 1.5mg Tablets (NEW) | Red | For smoking cessation |
Inpatient initiation by hospital stop smoking teams only.
Short-term, 25 day course. Full course to be dispensed at, or, prior to discharge. Patient followed up by the hospital stop smoking team during inpatient stay and after discharge.
In case of treatment failure, the treatment should be discontinued and may be resumed after 2 to 3 months
|
| DEL NIDO CARDIOPLEGIA (NEW) | Red | Cardioplegia in neonatal cardiac surgery | |
| DUPILUMAB (Dupixent®) (NEW) | Red | For Treating Severe Chronic Rhinosinusitis with Nasal polyps |
As per NICE TA1134 Funding: 18th May 2026 |
| DUPILUMAB (Dupixent®) (NEW) | Red | For Maintenance Treatment of Uncontrolled chronic obstructive pulmonary disease with raised Blood Eosinophils |
Funding from: 24th June 2026 |
| GUANFACINE (UPDATED) | Orange | ADHD - Adult |
Adult Full SCA and Request Form |
| METHYLPHENIDATE (UPDATED) | Orange | Excessive sleepiness caused by narcolepsy | |
| NORTRIPTYLINE (NEW) | Green | Use if amitriptyline not tolerated |
Second Choice Not licensed for use in neuropathic pain. Note tablets are usually more cost effective then capsules Exception is 50mg tablets are very expensive and should not be used in LLR. It is much more cost effective to use 2 x 25mg tablets.
|
| ORALTEK (Oraltek®) (NEW) | Red | Sublingual immunotherapy for horse allergy | |
| RIMEGEPANT (Vydura®) (UPDATED) | Green | Prophylaxis of migraine |
For preventing episodic migraine in adults who have at least 4 and fewer than 15 migraine attacks per month, only if at least 3 preventative treatments have not worked in line with NICE TA906. To be prescribed in line with the LLR Migraine pathway |
| RUXOLITINIB CREAM (Opzelura®) (NEW) | Red | For Treating Non-Segmental Vitiligo in People 12 years and Over |
Funding from: 15th June 2026 |
| SUCRALFATE ORAL (NEW) | Yellow |
On advice of gastroenterology when other treatments are unsuitable for Treatment of duodenal ulcer, gastric ulcer, chronic gastritis, and the prophylaxis of gastrointestinal haemorrhage from stress ulceration in seriously ill patients |
|
| SULFASALAZINE | Orange | Rheumatological disease | |
| SYSTANE® ULTRA preservative free eye drops (UPDATED) | Yellow | Ocular lubricant |
Evaporative Dry Eye & Meibomian Gland Dysfunction only |
| TARGETED-RELEASE BUDESONIDE (Kinpeygo®) (UPDATED) | Red | For treating Primary IgA Nephropathy |
In line with NICE TA1128 Funding: 4th May 2026 |
Recent documents from LLR APC and TAS
Date added: 12th May 2026
Date added: 12th May 2026
Date added: 12th May 2026
Date added: 12th May 2026
Date added: 12th May 2026
Date added: 6th May 2026
Date added: 6th May 2026
Date added: 14th Apr 2026
Date added: 14th Apr 2026
Date added: 3rd Oct 2024
Date added: 6th Sep 2024
Date added: 29th Dec 2022
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more